First published 9/28/2026, 7:40:15 PM · Last updated 9/28/2026, 7:40:15 PM

Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort

A journal article published by Springer reports real-world evidence on primary G-CSF prophylaxis in patients treated with sacituzumab govitecan for metastatic triple-negative breast cancer from a multinational cohort. The excerpt provides only publisher and content-type information and no study results or details.

Categories: public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 3/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 6/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The article addresses clinical prophylaxis practice in a specific cancer treatment context and may be of interest to clinicians and researchers.

Sources

Primary G-CSF prophylaxis in sacituzumab govitecan–treated mTNBC: real-world evidence from a multinational CEBCC-102 cohort

Report an issue